Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Lambert-Eaton myasthenic syndrome (LEMS) Clinical criteria: The condition must not be any of: (i) myasthenia gravis, (ii) Guillain-Barre syndrome. Treatment criteria: Must be treated by a prescriber type identifying as at least one of the following: (i) a clinical immunologist, (ii) a neurologist, (iii) a medical practitioner working under the direct supervision of one of these mentioned specialists.
“Amifampridine is a broad-spectrum potassium channel blocker.”
“Following oral administration of a single 20 or 30 mg dose of RUZURGI to healthy volunteers, the apparent oral clearance (CL/F) of amifampridine was 149 to 214 L/h, the average elimination half-life (t1/2) was 3.6 to 4.2 hours. The average t1/2 of the 3-N-acetyl amifampridine metabolite was 4.1 to 4.8 hours.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Amifampridine is not metabolised by cytochrome P450 (CYP)1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4.”